Outcome of Board Meeting

RPG LIFE SCIENCES LIMITED Regd. Off.: RPG House 463, Dr. Annie Besant Road Worli, Mumbai 400030, India Tel: +91-22-24981650 / 66606375 Fax: +91-22-24970127 RPG LIFE SCIENCES Email: info@rpglifesciences.com www.rpglifesciences.com CIN: l24232MH2007PLC169354 July 28, 2026 The Manager BSE Limited Listing Department Corporate Relationship Department National Stock Exchange of India Limited Floor Exchange Plaza, 5th Floor 25, P.J. Towers Plot No. C1, ‘G’ Block, Bandra-Kurla Complex Dalal Street Bandra (East), Mumbai 400 051. Mumbai 400 001. Symbol: RPGLIFE Scrip code: 532983 Dear Sir/Madam, Sub: Outcome of Board Meeting of the Company held on July 28, 2026. In terms of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its meeting held on Tuesday, July 28, 2026, inter-alia considered and unanimously approved, the unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2026, together with Limited Review Reports issued by the Statutory Auditors of the Company are enclosed herewith in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting commenced at 03:00 p.m. and concluded at 6.30 p.m. Kindly take the same on record. Thanking you, Yours faithfully, For RPG Life Sciences Limited Rajesh Shirambekar Head – Legal & Company Secretary Encl.- as above An ~»RPG Company SR BC & COLLP 12th Floor, The Ruby 29 Senapati Bapat Marg Dadar (West) Chartered Accountants Mumbai -400 028, India Tel : +91 22 6819 8000 Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended Review Report to The Board of Directors RPG Life Sciences Limited I. We have reviewed the accompanying statement of unaudited standalone financial result of RPG Life Sciences Limited (the "Company") for the quarter ended June JO, 2026 (the "Statement") attached herewith, being submitted by the Company pur uant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations"). 2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) '·Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement i free of material misstatement. A review of interim tinancial information consists of making inquiries. primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable u to obtain a surance that we would become aware of all significant matter that might be identitied in an audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material mi statement. For S R B C & CO LLP Chartered Accountants ICAI Firm registration number: 324982E/E300003 per Aruna Kumaraswamy Partner Membership No.: 2 I 9350 UDIN: 2-~'2\9 350 E: 'U. . PEP b 13 / Place: Mumbai Date: July 28, 2026 S R BC & CO LLP, a limited liabiHty Partnership with LLP Identity No. AAB-4318 Regd. Office: 22, Camac Street. Block 'B', 3rd Floor, Kolkata-700 016 £ RPG LIFE SCIENCES LIMITED Registered Office : RPG House, 463, Dr. Annie Besant Road, Worli, Mumbai 400030, India. Tel: +91-22-69757100 Email: info@rpglifesciences.com RPO LIFE SCIENCES www.rpglifesciences.com CIN: L24232MH2007PLC169354 STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026 (Rs. in Lakhs) Quarter ended Year ended Particulars 30-06-2026 31-03-2026 30-06-2025 31-03-2026 Unaudited Audited Unaudited Audited I Revenue from Operations 19,569 17,689 16,892 70,752 2 Other Income (Refer note 3(a)) 416 1,236 523 2,554 3 Total Income (1+2) 19,985 18,925 17,415 73,306 4 Expenses (a) Cost of Materials Consumed 3,768 3,643 3,204 13,598 (b) Purchases of Stock-in-Trade 3,953 2,263 3,306 13,810 ( C) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade (906) 153 (508) (2,199) (ct) Employee Benefits Expense 3.776 3,630 3,370 14,148 (e) Finance Cost 63 39 I 3 89 (f-) Depreciation and Amortisation Expense 590 574 514 2,148 (g) Other Expenses 4,620 4,713 3,973 16,682 Total Expenses 15,864 15,015 13,872 58,276 5 Profit before e·xceptional items and tax (3-4) 4,121 3,910 3,543 15,030 6 Exceptional items (net) (Refer Note 3) - 110 - 390 7 Profit before tax 4,121 4,020 3,543 15,420 8 Income tax expenses a. Current Tax 1,076 721 907 3,475 b. Deferred Tax ( 12) 309 7 428 Total tax expenses 1,064 l,o30 914 3,903 9 Profit for the period (7-8) 3,057 2,990 2,629 11,517 10 Other Comprehensive Income (i) Items that will not be reclassified to Profit or Loss (20) 10 (2) (86) (ii) Income tax relating to items that will not be reclassified to Profit or Loss 5 (2) I 22 Other Comprehensive Income/ (Loss) Net of Tax ( 15) 8 (I) (64) II Total Comprehensive Income for the period (9+10) 3,042 2,998 2,628 11,453 12 Paid-up Equity Share Capital IJ23 1,323 1,323 1,323 (Face Value Rs. 8/-each) 13 Other Equity 59,214 14 Earnings per Share (of Rs. 8/-each) (not annualised for the quarter): (a) Basic (in Rs.) 18.49 18.08 15.90 69.64 (b) Di luted ( in Rs.) 18.49 18.08 15.90 69.64 SIGNED FOR IDENTIFICATION SR BC & CO LLP MUMBAI An ~»Rr'G Company RPG LIFE SCIENCES LIMITED Registered Office : RPG House, 463, Dr. Annie Besant Road, Worli, Mumbai 400030, India. Tel: +91-22-69757100 RPG LIFE SCIENCES Email: info@rpglifesciences.com www.rpglifesciences.com CIN: L24232MH2007PLC169354 Notes: I. The above unaudited standalone financial results of the Company have been reviewed and recommended by the Audit Committee and have been approved by the Board of Directors at their respective meeting held on July 28, 2026. 2. The Company operates in only one reportable business segment i.e. Pharmaceuticals. 3. Exceptional items: (Rs. in Lakhs) Quarter ended Year ended Exceptional 30-06-2026 31-03-2026 30-06-2025 31-03-2026 Income/ (Expenses) Unaudited Audited Unaudited Audited Net impact of Insurance claim on loss arising on account of 1,087 2,475 fire incident -Refer note 3(a) Impact of New Labour Codes -Refer note 3(b) (61) (1,169) Impairment of Intangible Assets Under Development (916) (916) (IAUD) [Showing first 8,000 characters — download PDF for full document]